Vaccines Market COVID-19 Impact Analysis, Industry Trends, Business Strategies, Opportunities and Forecast to 2027 Discussed in a New Market
                     Vaccines Market 
Vaccines Market Forecast to 2027 - COVID-
19 Impact and Global Analysis by 
Technology (Recombinant Vaccines, 
Conjugate Vaccines, Live Attenuated 
Vaccines, Inactivated and Subunit Vaccines, 
and Toxoid Vaccines); Disease Indication 
(DTP (Diphtheria Tetanus toxoids and 
Pertussis), Influenza, Hepatitis, Respiratory 
Syncytial Virus (RSV), Dengue, 
Cytomegalovirus (CMV), and Other 
Diseases); Route of Administration (Oral, 
Injectable, and Other Routes of 
Administration); Patient Type (Pediatric 
Patients, and Adult Patients) and 
Geography
Vaccines Market 
Current and future Market Scenario
 According to The Insight Partners market research study titled ‘Vaccines Market - Global Analysis and Forecasts by 
Technology, Disease Indication, Route of Administration, and Patient Type. The global vaccines market is expected to 
reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018. The market is estimated to grow with a CAGR of 6.5% from 
2019-2027. The report highlights the trends prevalent in the global vaccines market and the factors driving the market 
along with those that act as deterrents to its growth.
 The vaccines market by technology is segmented into Recombinant vaccines, Conjugate Vaccines, Live Attenuated 
Vaccines, Inactivated Vaccines, and Toxoid Vaccines. In 2018, the conjugate vaccines segment held a largest market share 
of 65.1% of the vaccines market, By Technology. This segment is also expected to dominate the market in 2027 as they 
are the most effective forms of immunization, used to prevent diseases in both infants and adults. Moreover, the similar 
segment is anticipated to also witness the fastest growth rate of 6.7% during the forecast period, 2019 to 2027 owing to 
the increasing demand for drugs to treat the disease.
 Driving factors such as, growing focus on immunization programs, increasing support for vaccine development, rising 
prevalence of infectious diseases. However, the complexity and cost of vaccine manufacturing and soaring costs of 
vaccines are likely to pose a negative impact on the market growth. On the other hand, robust pipeline of vaccines is 
likely to have a positive impact on the growth of the global vaccines market in the coming years.
Key Findings
 The market players are focused towards bringing new and innovative products and services to sustain their position in 
the market. For instance, in December, 2018, The European Commission has granted marketing authorization for 
Dengvaxia, Sanofi’s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by 
the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to approve use of the 
dengue vaccine in European endemic areas. The developments performed by the companies are helping the market to 
grow in the coming years.
Market Insights
Rising prevalence of infectious diseasesis expected to boost the market growth over the years 
In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These 
emerging infectious diseases are a burden on public health but have also an impact on global economies. The new 
diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. 
There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. 
According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to 
infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with 
Hepatitis B and 10 million with Hepatitis C). 
Vaccines Market 
 
Market Segments
By Technology (Recombinant Disease Indication (DTP  
Vaccines, Conjugate Vaccines, Live (Diphtheria Tetanus toxoids Route of Administration (Oral, 
Attenuated Vaccines, Inactivated and Pertussis), Influenza, Injectable, and Other Routes of 
and Subunit Vaccines, and Toxoid Hepatitis, Respiratory Administration); Patient Type 
Vaccines)
Syncytial Virus (RSV), Dengue, (Pediatric Patients, and Adult 
Cytomegalovirus (CMV), and Patients)
Other Diseases)
Vaccines Market 
Dominating Segments
 
 A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A 
  vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often 
made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The 
agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further 
recognize and destroy any of the microorganisms associated with that agent that it may encounter in the 
future.
 The scope of the vaccines market includes technology, disease indication, route of administration, patient 
type, and region. The market for vaccinesis analyzed based on regions such as North America, Europe, Asia 
Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis 
of the vaccines market emphasizing on various parameters such as market trends, technological 
advancements, market dynamics, and competitive landscape analysis of leading market players across the 
world
Dominating Segments
Product Insights
Increasing Support for Vaccine Development
 In addition to the funds from traditional research-funding institutions, the Gates Foundation has invested 
hundreds of millions of dollars in R&D of new vaccines against the leading killers of children and adults 
everywhere. GAVI has established public-private partnerships to accelerate late-stage development and 
introduction of priority vaccines against diseases such as rotavirus and pneumococcus. These partnerships are 
designed to work with governments, donors, and industry to streamline demand, supply, and financing decisions. 
They coordinate and fund the efforts of partners supporting national decision makers whether to introduce these 
new products, ensuring a reliable and sustainable supply of affordable vaccine to developing countries, and 
reducing risks and creating incentives for private investment to ensure access to the product. Global Vaccine Fund 
commits $150 Million in vaccines and funding over five years to 13 developing countries. Countries will receive 
financial and technical assistance in order to strengthen basic immunization systems and to introduce newer, 
under-used vaccines such as hepatitis B and Haemophilusinfluenzae type b (Hib). Some countries will receive 
support in both areas. Thus the growing support for vaccine development is likely to favor market growth.
 Download PDF Brochure https://www.theinsightpartners.com/sample/TIPRE00015468/ 
Dominating Segments
The report segments the global Vaccines market as follows:
By Technology
Recombinant vaccines
Conjugate Vaccines
Live Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
By Disease Indication
DTP (diphtheria, tetanus, and pertussis)
Influenza
Hepatitis
Dengue
Cytomegalovirus (CMV)
Respiratory Syncytial Virus (RSV)
Other Diseases
Dominating Segments
By Route of Administration
Oral
Injectable
Other
 
By Patient Type
Adult Patients
Pediatric Patients
Vaccines Market  
Leading Players
Company Profiles in Vaccines Market are:
PFIZER INC
GlaxoSmithKline plc.
Merck & Co., Inc.
Sanofi
Johnson & Johnson Services, Inc
Panacea Biotec Limited
Astellas Pharma Inc.
NOVAVAX, INC.
VBI Vaccines Inc.
Bavarian Nordic
  REGIONAL FRAMEWORK
REGIONAL FRAMEWORK
 
 Vaccines Market 
 
        
Access Full Research Report at: 
https://www.theinsightpartners.com/reports/vaccines-market
 
Thank You! 
Thank You!